Tag: MONOGRAPH

  • 9-Me-BC

    Beta-carboline alkaloid, dopaminergic neuroprotective small molecule (capsule format)

    A 182 Da methylated beta-carboline alkaloid characterized for dopaminergic neuroprotective effects, increased dopamine neuron differentiation, and BDNF expression in animal models.

    Abstract

    9-Methyl-beta-carboline (9-Me-BC; CAS 2521-07-5; molecular formula C12H10N2; molecular weight 182.22) is a small-molecule beta-carboline alkaloid bearing a methyl substituent on the 9-position indole nitrogen. The compound is a member of the broader beta-carboline family, naturally occurring alkaloids found in trace concentrations in many plants (notably the harmal family of psychoactive plants used in traditional preparations) and present at low concentrations in mammalian tissues including human plasma. The synthetic 9-methylated variant has attracted research interest beginning in the 2010s for a distinctive pharmacological profile that combines dopaminergic neuroprotective effects, increased dopamine neuron differentiation in cell culture, and elevated BDNF expression in rodent brain. Unlike many psychoactive beta-carbolines (harmaline, harmine, others), 9-Me-BC has substantially reduced affinity for the monoamine oxidase A enzyme and substantially reduced psychoactive effects at the doses used in published preclinical work. There is no FDA-approved IND for 9-Me-BC in any indication. The principal limitations on the strength of the evidence are the relatively short duration of the published research record, dominance of a small number of laboratories (primarily in the German neuroscience research community), and the absence of human clinical data.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • SS-31

    Synthetic tetrapeptide mitochondrial-targeting cardiolipin-binding peptide

    A 4-amino-acid mitochondrial-targeting peptide developed at Cornell University, characterized for binding to cardiolipin in the inner mitochondrial membrane and protecting mitochondrial function in oxidative stress.

    Abstract

    SS-31 (sequence D-Arg-Dmt-Lys-Phe-NH2, also known as elamipretide, Bendavia, MTP-131; CAS 736992-21-5; molecular formula C32H49N9O5; molecular weight 639.79) is a synthetic tetrapeptide developed in the laboratory of Hazel Szeto at Cornell University Medical College beginning in the early 2000s. The peptide is the most extensively characterized member of the Szeto-Schiller (SS) series of mitochondrial-targeting tetrapeptides. The biological mechanism is binding to cardiolipin in the inner mitochondrial membrane, which protects the membrane lipid environment from peroxidation, stabilizes the supercomplexes of the electron transport chain, and improves mitochondrial efficiency in conditions of oxidative stress or mitochondrial dysfunction. The compound is the active pharmaceutical ingredient in elamipretide (Bendavia), which has been advanced through Phase 2 and Phase 3 clinical trials by Stealth BioTherapeutics for primary mitochondrial myopathies, age-related macular degeneration (dry AMD with geographic atrophy), Barth syndrome, and other mitochondrial dysfunction indications. The clinical record is mixed; the most-promising results have come in Barth syndrome and primary mitochondrial myopathy. The compound is not approved by any regulatory authority for human or veterinary use as of this revision; recent FDA review in geographic atrophy resulted in a complete response letter requesting additional data. The Kodiac biolabs lot of record is SW260307, manufactured 7 March 2026 by Xian Sowu Biotech, with a vendor COA assay of 99.62 percent and a supplementary HPLC area-percent of 99.18 percent at 220 nm; both documents are archived on the lab results page.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Dihexa

    Angiotensin IV analog (procognitive small peptidomimetic)

    A small angiotensin IV analog with a contested mechanism of action, a high-profile commercialization failure, and a literature record selectively retracted in 2025.

    Abstract

    Dihexa, also known as PNB-0408 and N-hexanoic-Tyr-Ile-(6) amino-hexanoic amide, is a hexapeptide-derived small molecule developed in the Harding laboratory at Washington State University as a procognitive analog of angiotensin IV. It was foundationally hypothesized to act through agonism of the hepatocyte growth factor (HGF) / c-Met receptor system, a mechanism that promised oral bioavailability, blood-brain barrier penetration at picomolar potency, and rapid synaptogenesis in cortical and hippocampal neurons. Between 2011 and 2014, four peer-reviewed publications established the compound’s commercial pipeline and underwrote the formation of Athira Pharma, a publicly traded biotechnology firm that raised over 204 million dollars in a 2020 initial public offering. Each of these four publications was retracted by the Journal of Pharmacology and Experimental Therapeutics in April 2025 following findings of academic misconduct, specifically the splicing and duplication of Western blot bands across distinct experimental conditions. The Department of Justice settled a False Claims Act qui tam action against Athira Pharma in January 2025 for 4.07 million dollars. The clinical lead derived from this program, fosgonimeton (ATH-1017, NDX-1017), failed to meet primary endpoints in the LIFT-AD Phase 2/3 trial in mild-to-moderate Alzheimer disease and the SHAPE Phase 2 trial in dementia with Lewy bodies. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • 5-Amino-1MQ

    Small-molecule selective NNMT inhibitor (capsule format)

    A 159 Da quinolinium small molecule that selectively inhibits nicotinamide N-methyltransferase, characterized for effects on adipose metabolism and skeletal muscle stem cell function.

    Abstract

    5-Amino-1-methylquinolinium iodide (5-Amino-1MQ; CAS 42464-96-0 for the iodide salt; molecular formula C10H11N2+ for the cation; molecular weight 159.21 for the cation and 286.11 for the iodide salt) is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT, EC 2.1.1.1), the enzyme that methylates nicotinamide to N1-methylnicotinamide using S-adenosylmethionine (SAM) as the methyl donor. NNMT activity diverts nicotinamide away from the NAD+ salvage pathway and consumes SAM, which connects NNMT activity to both the cellular NAD+ pool and the methylation potential of the cell. NNMT is overexpressed in many cancers (where it has been characterized as an “oncometabolic” enzyme) and in obesity-associated white adipose tissue, where it has been linked to insulin resistance and to the metabolic dysfunction phenotype. Selective NNMT inhibitors including 5-Amino-1MQ have been developed primarily by academic medicinal chemistry groups beginning in the late 2010s and have been characterized in cell culture, in vivo rodent obesity and aging models, and in skeletal muscle stem cell and aging models. There is no FDA-approved IND for 5-Amino-1MQ in any indication. The compound is not a regulated drug substance in the United States, the European Union, or Japan. The principal limitations on the strength of the evidence are the relatively short duration of the published research record and the limited human safety and efficacy data.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • NAD+

    Pyridine nucleotide cofactor, redox carrier and substrate for sirtuins, PARPs, and CD38

    An obligate intracellular dinucleotide cofactor essential for hundreds of enzymatic reactions, supplied for research use as the oxidized free acid form.

    Abstract

    Nicotinamide adenine dinucleotide (NAD+; CAS 53-84-9; molecular formula C21H27N7O14P2; molecular weight 663.43) is a small-molecule pyridine dinucleotide cofactor that functions in three biologically distinct roles: as the dominant cellular electron-transfer cofactor in oxidative metabolism (where it cycles between the oxidized NAD+ and reduced NADH forms), as the substrate for the sirtuin family of NAD+-dependent deacetylases (which hydrolyze NAD+ to nicotinamide and ADP-ribose), and as the substrate for poly-ADP-ribose polymerases (PARPs) and the CD38 ecto-enzyme (both of which also consume NAD+). Cellular NAD+ concentrations are tightly regulated and decline substantially with age in humans and other mammals; the age-related decline correlates with reduced sirtuin activity, impaired DNA damage repair, and a constellation of metabolic dysfunctions that has motivated substantial research interest in NAD+ supplementation as a geroprotective intervention. The research-grade product supplied as “NAD+” is the oxidized free acid form, which has poor oral bioavailability. The precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are more efficiently absorbed and are converted intracellularly to NAD+. The compound is not approved by any regulatory authority for human or veterinary use as a therapeutic; NAD+ is also widely available as a food supplement under separate regulatory frameworks.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • BPC-157

    Pentadecapeptide (gastric BPC fragment)

    A 15-amino-acid sequence derived from a gastric protective protein, broadly studied in tendon, ligament, vascular, and gut repair models.

    Abstract

    BPC-157, formally pentadecapeptide BPC 157 (Body Protection Compound 157), is a 15-residue partial sequence isolated from a larger gastric protective protein found in human gastric juice. The sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (CAS 137525-51-0; molecular formula C62H98N16O22; molecular weight 1419.55) was originally characterized in the 1990s by the Sikiric group at the University of Zagreb, who have authored the majority of the published preclinical record. Reported activities span tendon and ligament healing in transection models, vascular reorganization through nitric oxide synthase modulation and VEGF receptor 2 engagement, gastrointestinal mucosal protection, dopaminergic system modulation, and GH receptor crosstalk. Routes studied include intraperitoneal, intramuscular, subcutaneous, oral, and topical administration in rodent models; oral bioavailability is unusual for a peptide of this length and is attributed to the parent compound’s evolutionary role in the gut. Human pharmacokinetic data are sparse; one published Phase 1 single-ascending-dose study has been reported. BPC-157 is not approved by any regulatory authority for human or veterinary use. The literature base is dominated by a single research group, which is the principal limitation on the strength of the evidence; independent replications of the most-cited findings are limited but growing. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Epitalon

    Synthetic tetrapeptide telomerase modulator and bioregulator

    A 4-residue synthetic peptide developed in St. Petersburg, studied principally for telomerase modulation, pineal function, and circadian rhythm endpoints in a literature dominated by a single research consortium.

    Abstract

    Epitalon (also Epithalon, Epithalone; sequence Ala-Glu-Asp-Gly; CAS 307297-39-8; molecular formula C14H22N4O9; molecular weight 390.35) is a synthetic tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues beginning in the 1980s. The compound was designed as a synthetic analog of an active fragment isolated from a bovine pineal gland extract (the original “Epithalamin” preparation) and is reported to modulate pineal melatonin secretion, support telomerase activity in cultured cell lines, and influence circadian gene expression. The published preclinical record is dominated almost entirely by the Khavinson group and affiliated St. Petersburg laboratories, which is the principal methodological concern in any rigorous review of the literature; independent replication of the most-cited findings (telomerase induction, lifespan extension in rodent models) is sparse. A small number of human studies have been published, primarily uncontrolled or small-sample clinical observation studies in elderly populations, which have been critically reviewed for methodological limitations. Reported activities span pineal function modulation, antioxidant effects, telomere length stabilization in cell culture models, and reduction of age-related pathology markers in animal studies. The compound is not approved by any regulatory authority for human or veterinary use outside of certain Russian clinical contexts where Epithalamin (the parent extract) has historical use. Investigators should approach the literature with awareness of the single-laboratory dominance and the limited independent replication.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • TB-500

    Synthetic peptide fragment of thymosin beta-4

    A 43-residue acetylated synthetic peptide derived from the actin-sequestering protein thymosin beta-4, studied for tissue repair, cell migration, and angiogenic endpoints.

    Abstract

    TB-500 is the common research-grade designation for a synthetic acetylated peptide whose primary sequence is a fragment of human thymosin beta-4 (Tbeta4), a 43-residue actin-binding protein expressed at high concentration in platelets, leukocytes, and many other cells. The most frequently cited research-grade preparation is the full-length Tbeta4 sequence (43 amino acids; molecular weight approximately 4963 Da; CAS 77591-33-4) acetylated at the N-terminus to mimic the native post-translational modification. A small minority of vendor literature has used “TB-500” to refer to a shorter active fragment (LKKTETQ, residues 17 through 23 of Tbeta4), which is a different molecule with a different mass; investigators should confirm by mass spectrometry which sequence has been supplied. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Ipamorelin

    Pentapeptide growth hormone secretagogue, ghrelin receptor agonist

    A 5-residue selective growth hormone secretagogue developed at Novo Nordisk in the late 1990s, characterized by GH release without coincident ACTH or prolactin stimulation.

    Abstract

    Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; CAS 170851-70-4; molecular formula C38H49N9O5; molecular weight 711.86) is a synthetic pentapeptide growth hormone secretagogue (GHS) developed at Novo Nordisk in the mid-1990s and disclosed in a 1998 paper by Raun and colleagues. Ipamorelin is a selective agonist of the growth hormone secretagogue receptor 1a (GHS-R1a, the ghrelin receptor), the receptor through which the endogenous peptide ghrelin and the small-molecule MK-0677 also act. Selective activation of GHS-R1a triggers pulsatile growth hormone (GH) release from the anterior pituitary without the concurrent stimulation of cortisol, ACTH, or prolactin that complicates the pharmacology of older GHS compounds (GHRP-2, GHRP-6, hexarelin). The selectivity profile is the basis on which Ipamorelin remains the most-cited research-grade GHS in the post-2010 literature. The compound was advanced through Phase 2 trials by Helsinn Therapeutics for postoperative ileus before development was discontinued for commercial reasons. Reported preclinical activities include dose-dependent GH pulse induction, increased IGF-1 axis activity over multi-day administration, modest effects on appetite (smaller than ghrelin’s), and accelerated bone mineral density gains in osteopenic rodent models. The compound is not approved by any regulatory authority for human or veterinary use. The literature base is solid for the basic pharmacology but limited for long-term safety data in humans; the clinical record is principally from a single short-term ileus indication.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CJC-1295 (No DAC)

    Synthetic 29-residue analog of growth hormone-releasing hormone

    A 29-amino-acid GHRH analog with four point substitutions that confer enzymatic stability against dipeptidyl peptidase 4, the principal degradation pathway for native GHRH.

    Abstract

    CJC-1295 (No DAC), often abbreviated CJC-1295 nDAC and known in the literature as modified GRF(1-29) or simply Mod-GRF, is a synthetic 29-residue analog of human growth hormone-releasing hormone (GHRH) bearing four point mutations relative to the native sequence (CAS 446036-97-1; molecular weight 3367.94). The substitutions are tyrosine-1 to D-alanine (DPP-4 resistance), alanine-8 to glutamine (improved chemical stability), arginine-15 to glutamine (DPP-4 resistance and stability), and asparagine-27 to leucine (improved hydrophobicity and resistance to deamidation). The result is a GHRH analog with substantially extended biological half-life relative to native GHRH (which has a serum half-life under 10 minutes due to rapid DPP-4 cleavage at the N-terminal tyrosine). CJC-1295 nDAC retains the receptor specificity of native GHRH and stimulates pituitary somatotrophs through the GHRH receptor, producing a pulsatile GH release pattern. The “DAC” suffix in the related compound CJC-1295 with DAC refers to a drug affinity complex (a maleimidopropionic acid linker that covalently attaches to serum albumin) that further extends the half-life from approximately 30 minutes to multiple days; the No DAC version omits the linker and the prolonged albumin binding. The two compounds have different pharmacokinetic profiles and different appropriate use cases. CJC-1295 nDAC was originally developed at ConjuChem, Inc., as the parent platform for the DAC-modified version that progressed to Phase 2 trials. The compound is not approved by any regulatory authority for human or veterinary use.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.